Eitan Z Rath1, Zadik Hazan, Konstantin Adamsky, Arieh Solomon, Zvi I Segal, Leonard A Levin. 1. Ophthalmology Department (EZR, ZIS), Galilee Medical Center, Nahariya; and Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Regenera Pharma Ltd (ZH, KA), Israel; Goldschleger Eye Research Institute (AS), Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel; and Departments of Ophthalmology and Visual Sciences, Neurology and Neurosurgery (LAL), McGill University, Montreal, Canada.
Abstract
BACKGROUND: No proven treatment exists for nonarteritic anterior ischemic optic neuropathy (NAION), either in the acute or late phase. OBJECTIVE: To assess safety and changes in visual function and structure after RPh201/placebo treatment in participants with previous NAION. DESIGN AND SETTING: Phase 2a, single-site, prospective, randomized, placebo-controlled, double-masked trial (registration NCT02045212). MAIN OUTCOMES MEASURES: Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), visual fields, retinal nerve fiber layer, and visual evoked potential at weeks 13, 26, and after a 13-week wash-out ("off-drug") period; and safety. STUDY POPULATION: Twenty-two participants aged 18 years or older with previous NAION. INTERVENTION(S): RPh201 (20 mg) or placebo (cottonseed oil vehicle) administered subcutaneously twice weekly at the study site. RESULTS:Thirteen men and 9 women were randomized, of which 20 completed all visits. The mean (±SD) age was 61.0 ± 7.6 years. In a post hoc analysis, after 26 weeks of treatment, BCVA improved by ≥15 letters in 4/11 (36.4%) eyes with RPh201, compared to 1/8 (12.5%) eyes with placebo (P = 0.24). Overall, 7/11 (63.6%) of participants on RPh201 showed some improvement in BCVA, compared with 3/8 (37.5%) on placebo (P = 0.26). Improvement in BCVA from a calculated baseline was 14.8 ± 15.8 letters for RPh201 and 6.6 ± 15.3 for placebo (P = 0.27). Of the 154 adverse effects (AEs), 52 were considered related to the study procedures/treatment. Across the study and 1,017 injections, the most frequently reported AE was injection site pain (23 events in 5 participants). There were no clinically significant changes in vital signs or laboratory values. CONCLUSIONS: This Phase 2a was designed to assess safety, feasibility, and explore potential efficacy signals in treating previous NAION with RPh201. No safety concerns were raised. The results support a larger trial in patients with previous NAION.
RCT Entities:
BACKGROUND: No proven treatment exists for nonarteritic anterior ischemic optic neuropathy (NAION), either in the acute or late phase. OBJECTIVE: To assess safety and changes in visual function and structure after RPh201/placebo treatment in participants with previous NAION. DESIGN AND SETTING: Phase 2a, single-site, prospective, randomized, placebo-controlled, double-masked trial (registration NCT02045212). MAIN OUTCOMES MEASURES: Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), visual fields, retinal nerve fiber layer, and visual evoked potential at weeks 13, 26, and after a 13-week wash-out ("off-drug") period; and safety. STUDY POPULATION: Twenty-two participants aged 18 years or older with previous NAION. INTERVENTION(S): RPh201 (20 mg) or placebo (cottonseed oil vehicle) administered subcutaneously twice weekly at the study site. RESULTS: Thirteen men and 9 women were randomized, of which 20 completed all visits. The mean (±SD) age was 61.0 ± 7.6 years. In a post hoc analysis, after 26 weeks of treatment, BCVA improved by ≥15 letters in 4/11 (36.4%) eyes with RPh201, compared to 1/8 (12.5%) eyes with placebo (P = 0.24). Overall, 7/11 (63.6%) of participants on RPh201 showed some improvement in BCVA, compared with 3/8 (37.5%) on placebo (P = 0.26). Improvement in BCVA from a calculated baseline was 14.8 ± 15.8 letters for RPh201 and 6.6 ± 15.3 for placebo (P = 0.27). Of the 154 adverse effects (AEs), 52 were considered related to the study procedures/treatment. Across the study and 1,017 injections, the most frequently reported AE was injection site pain (23 events in 5 participants). There were no clinically significant changes in vital signs or laboratory values. CONCLUSIONS: This Phase 2a was designed to assess safety, feasibility, and explore potential efficacy signals in treating previous NAION with RPh201. No safety concerns were raised. The results support a larger trial in patients with previous NAION.
Authors: M J Kupersmith; L Frohman; M Sanderson; J Jacobs; J Hirschfeld; C Ku; F A Warren Journal: J Neuroophthalmol Date: 1997-12 Impact factor: 3.042
Authors: Nancy J Newman; Roberta Scherer; Patricia Langenberg; Shalom Kelman; Steven Feldon; David Kaufman; Kay Dickersin Journal: Am J Ophthalmol Date: 2002-09 Impact factor: 5.258
Authors: Dean M Cestari; Eric D Gaier; Peggy Bouzika; Taylor S Blachley; Lindsey B De Lott; Joseph F Rizzo; Janey L Wiggs; Jae H Kang; Louis R Pasquale; Joshua D Stein Journal: Ophthalmology Date: 2016-09-19 Impact factor: 12.079
Authors: Fang Sun; Kevin K Park; Stephane Belin; Dongqing Wang; Tao Lu; Gang Chen; Kang Zhang; Cecil Yeung; Guoping Feng; Bruce A Yankner; Zhigang He Journal: Nature Date: 2011-11-06 Impact factor: 49.962
Authors: Chunyang Wang; Michael Chopp; Rui Huang; Chao Li; Yi Zhang; William Golembieski; Mei Lu; Zadik Hazan; Zheng Gang Zhang; Li Zhang Journal: Front Neurosci Date: 2020-07-31 Impact factor: 4.677